Last Updated: 16 Sep 2024
Executive Summary
Haleon plc (HLN) is a leading global consumer healthcare company with a market capitalization of $47.87 billion. The company's stock price is currently trading at $10.51. Haleon has a strong financial position with an EBITDA of $2.6 billion and a profit margin of 9.66%. The company's revenue is growing at a modest rate and its earnings per share are expected to increase by 3.2% in the next quarter. Haleon has a strong competitive position and is well-positioned for long-term growth.
Company Overview
Haleon was formed in 2022 through the spin-off of the consumer healthcare business of GlaxoSmithKline plc. The company's portfolio includes a wide range of over-the-counter (OTC) medicines, vitamins, minerals, and supplements. Haleon's products are sold in over 100 countries and the company has a leading market position in many of its key markets.
Fundamental Analysis
Haleon's financial performance has been strong in recent years. The company's revenue has grown at a compound annual growth rate (CAGR) of 3.5% over the past five years. Haleon's EBITDA has also grown at a CAGR of 4.5% over the same period. The company's profit margin has remained relatively stable in recent years.
Haleon's balance sheet is also strong. The company has a low level of debt and a high level of cash. Haleon's return on assets (ROA) and return on equity (ROE) are both above industry average.
Technical Analysis
Haleon's stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also above 50, indicating that the stock is overbought.
Short Term Outlook
Haleon's stock price is expected to continue to trend higher in the short term. The stock is currently trading at a discount to its fair value and the company's fundamentals are strong. Haleon is also expected to benefit from the continued growth of the OTC market.
Long Term Outlook
Haleon is well-positioned for long-term growth. The company has a strong portfolio of products, a leading market position, and a strong financial position. Haleon is also expected to benefit from the continued growth of the OTC market.
Analyst Recommendations
Analysts are generally positive on Haleon. The consensus rating on the stock is "Buy." The average analyst target price is $11.05.
